Search

Your search keyword '"Špaček, J."' showing total 140 results
Start Over Author "Špaček, J."
140 results on '"Špaček, J."'

1. Rivers in the Czech Republic

Author

Rulík, M., Opatřilová, L., Jurajda, P., Špaček, J., Grulich, V., Zelenakova, Martina, editor, Fialová, Jitka, editor, and Negm, Abdelazim M., editor

Published
2020
Full Text
View/download PDF

5. Čistá intermitentní katetrizace močového měchýře.

Author

Šámal, V., Paldus, V., Špaček, J., and Broďák, M.

Abstract

Copyright of General Practitioner / Praktický Lékař is the property of Czech Medical Association of JE Purkyne and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Published
2022

9. Importance of basal fibroblast growth factor levels in patients with ovarian tumor

Author

Študent V, Andrýs C, Souček O, Špaček J, Tošner J, and Sedláková I

Subjects
Fibroblast Growth Factors, Ovarian Neoplasms, Ovarian Cysts, Humans, Female, Prospective Studies
Abstract

Evaluation of importance of serum levels of basic fibroblast growth factor (bFGF) in patients with ovarian cancer, patients with border-line ovarian tumor, patients with benign ovarian cyst and women with normal ovarian tissue.Prospective clinical study.Department of Gynecology and Obstetrics, Charles University, Faculty of Medicine in Hradec Kralove and University Hospital Hradec Kralove.Measurement of serum levels of bFGF by ELISA using reagents of company RD Systems prior to treatment in a total of 74 consecutive coming women.Serum level of bFGF from peripheral blood before treatment was significantly higher (plt; 0.05) in patients with newly diagnosed ovarian cancer (n = 22), Med = 10.35 pg/ml (1.2-46.2 pg/ml) compared to patients with a border-line ovarian tumor (n = 9), Med = 5.4 pg/ml (1.6-6.8 pg/ml), patients with benign ovarian cyst (n = 24), Med = 5.2 pg/ml (0.1-67.2 pg/ml), and to women with normal ovarian tissue (n = 19) Med = 4.3 pg/ml (0.9-13.4 pg/ml). There isnt strong linear correlation (Spearmans rank correlation coefficient = 0.208791) between the serum level of bFGF and CA125 collected from peripheral blood before primary surgery or neoadjuvant chemotherapy in a group of patients with ovarian cancer (n = 14). We have not found significance correlation between age and serum levels of bFGF in patients with ovarian cancer, with border-line ovarian tumor, with benign ovarian cyst and in women with normal ovarian tissue.Serum levels of bFGF in patients with ovarian cancer are significantly higher than in patients with a border-line ovarian tumor, with benign ovarian cyst and in women with normal ovarian tissue regardless of age of patients.

Published
2019

13. Olaparib maintenance therapy in patients (pts) with platinum-sensitive relapsed (PSR) ovarian cancer (OC) and stable disease (SD) following platinum-based chemotherapy

Author

Oza, A.M., primary, Cibula, D., additional, Oaknin, A., additional, Poole, C., additional, Mathijssen, R.H.J., additional, Sonke, G.S., additional, Colombo, N., additional, Špaček, J., additional, Vuylsteke, P., additional, Hirte, H., additional, Pfisterer, J., additional, Plante, M., additional, Hanker, L.C., additional, Fielding, A., additional, Haddad, V., additional, Chmielecki, J., additional, and Friedlander, M., additional

Published
2018
Full Text
View/download PDF

20. Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: A randomised phase 2 trial

Author

Oza, A, Cibula, D, Benzaquen, A, Poole, C, Mathijssen, R, Sonke, G, Colombo, N, Špaček, J, Vuylsteke, P, Hirte, H, Mahner, S, Plante, M, Schmalfeldt, B, Mackay, H, Rowbottom, J, Lowe, E, Dougherty, B, Barrett, J, Friedlander, M, Friedlander, M., COLOMBO, NICOLETTA, Oza, A, Cibula, D, Benzaquen, A, Poole, C, Mathijssen, R, Sonke, G, Colombo, N, Špaček, J, Vuylsteke, P, Hirte, H, Mahner, S, Plante, M, Schmalfeldt, B, Mackay, H, Rowbottom, J, Lowe, E, Dougherty, B, Barrett, J, Friedlander, M, Friedlander, M., and COLOMBO, NICOLETTA

Abstract

Background: The poly(ADP-ribose) polymerase inhibitor olaparib has shown antitumour activity in patients with platinum-sensitive, recurrent, high-grade serous ovarian cancer with or without BRCA1 or BRCA2 mutations. The aim of this study was to assess the efficacy and tolerability of olaparib in combination with chemotherapy, followed by olaparib maintenance monotherapy, versus chemotherapy alone in patients with platinum-sensitive, recurrent, high-grade serous ovarian cancer. Methods: In this randomised, open-label, phase 2 study, adult patients with platinum-sensitive, recurrent, high-grade serous ovarian cancer who had received up to three previous courses of platinum-based chemotherapy and who were progression free for at least 6 months before randomisation received either olaparib (200 mg capsules twice daily, administered orally on days 1-10 of each 21-day cycle) plus paclitaxel (175 mg/m2, administered intravenously on day 1) and carboplatin (area under the curve [AUC] 4 mg/mL per min, according to the Calvert formula, administered intravenously on day 1), then olaparib monotherapy (400 mg capsules twice daily, given continuously) until progression (the olaparib plus chemotherapy group), or paclitaxel (175 mg/m2 on day 1) and carboplatin (AUC 6 mg/mL per min on day 1) then no further treatment (the chemotherapy alone group). Randomisation was done by an interactive voice response system, stratified by number of previous platinum-containing regimens received and time to disease progression after the previous platinum regimen. The primary endpoint was progression-free survival according to Response Evaluation Criteria in Solid Tumors version 1.1, analysed by intention to treat. Prespecified exploratory analyses included efficacy by BRCA mutation status, assessed retrospectively. This study is registered with ClinicalTrials.gov, number NCT01081951, and has been completed. Findings: Between Feb 12 and July 30, 2010, 173 patients at 43 investigational sites in 12

Published
2015

Catalog

Books, media, physical & digital resources
See catalog results